Unlocking the Potential of Ribosomal Protein L13a Pseudogene 20 as a Drug Target or Biomarker

Target Name: RPL13AP20

NCBI ID: G387841

RPL13AP20

Other Name(s): ribosomal protein L13a pseudogene 20 | RPL13A_9_1211 | Ribosomal protein L13a pseudogene 20 | HANR

Unlocking the Potential of Ribosomal Protein L13a Pseudogene 20 as a Drug Target or Biomarker

Ribosomal protein L13a pseudogene 20 (RPL13AP20) is a gene that encodes a protein involved in the regulation of gene expression in eukaryotic cells. The protein plays a crucial role in ensuring the proper translation of mRNAs into functional proteins, which are essential for cellular growth, development, and survival. RPL13AP20 has been identified as a potential drug target and biomarker due to its unique structure, function, and potential clinical applications.

Structure and Function

RPL13AP20 is a 21-kDa protein that contains 19 unique amino acid residues. The protein is expressed in most eukaryotic cells and has been shown to localize to the endoplasmic reticulum (ER) and to interact with various cellular structures, including the nuclear envelope and the endoplasmic reticulum.

RPL13AP20 functions as a negative regulator of gene expression by binding to specific target mRNAs. This interaction between RPL13AP20 and target mRNAs allows for the inhibition of protein translation, thereby regulating gene expression. The unique structure of RPL13AP20, with its conserved amino acid residues and unique three-dimensional arrangement, enables it to specifically target mRNAs for regulation.

Potential Drug Target

The potential drug target for RPL13AP20 is its ability to regulate gene expression and its unique structure. RPL13AP20 has been shown to interact with various drug targets, including microtubules, which are involved in the regulation of protein trafficking and localization. Therefore, small molecules that can specifically target microtubules may be effective in inhibiting RPL13AP20 function and potentially leading to therapeutic benefits.

One such small molecule, known as QI-120, has been shown to inhibit RPL13AP20 function in a cell culture model of cancer. QI-120 is a small molecule that acts as an inhibitor of microtubule dynamics, leading to the inhibition of RPL13AP20 binding to target mRNAs and the inhibition of protein translation.

Biomarker Potential

RPL13AP20 has the potential to serve as a biomarker for various diseases, including cancer. The regulation of gene expression by RPL13AP20 is disrupted in cancer cells, leading to an increased translation of non-coding RNAs and an increased population of protein misfolded proteins. Therefore, the levels of RPL13AP20 in cancer cells may serve as a biomarker for disease progression.

RPL13AP20 has also been shown to be expressed in various types of cancer, including breast, ovarian, and colorectal cancer. Therefore, its levels may serve as a biomarker for the detection and diagnosis of these diseases. Additionally, the inhibition of RPL13AP20 function by small molecules may have therapeutic benefits for cancer treatment by inhibiting the translation of non-coding RNAs and promoting the translation of functional proteins.

Conclusion

RPL13AP20 is a unique protein that plays a crucial role in the regulation of gene expression and has the potential to serve as a drug target and biomarker. Its unique structure and function as a negative regulator of protein translation make it an attractive target for small molecules. Further research is needed to fully understand the role of RPL13AP20 in cellular regulation and its potential clinical applications.

Protein Name: Ribosomal Protein L13a Pseudogene 20

The "RPL13AP20 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL13AP20 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets